FACTORS ASSOCIATED WITH QUALITY OF LIFE AND FUNCTIONAL DISABILITY AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR AT LEAST SIX-MONTHS
Author(s)
Bae S1, Koh H2, Kim Y2
1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
OBJECTIVES: To determine characteristics of RA patients in Korea using disease-modifying anti-rheumatic drugs (DMARDs) for at least six months, and identify factors associated with poor health related outcomes. METHODS: A total of 2,000 RA patients age > 20, treated with DMARDs for at least six months, and signed informed consent were enrolled in this non-interventional, multicenter, cross-sectional observational study from December 2012 to June 2013. Health-related quality of life (HRQoL) was measured using EuroQuol 5D (EQ-5D) and functional disability was measured using Korean Health Assessment Questionnaire (KHAQ). Univariate and multivariate linear regression analyses were used to determine the association between patient characteristics and patient reported outcomes (PROs). RESULTS: Of all RA patients, 84% were females, patients with low disease activity score (DAS-28-ESR < 3.2) was 54%, while moderate (DAS-28-ESR 3.2-5.1) and high disease activity score (DAS-28-ESR > 5.1) were 38% and 7.6%, respectively. Mean EQ-5D index score and KHAQ score were 0.6 ± 0.28 and 0.7 ± 0.67, respectively. In multivariate analysis with both PROs, average HRQoL and functional disability score appeared to be worse in persons with older age compared to younger age (p < 0.001), and worse in females compared to males (p < 0.001). Compared to patients having lower DAS (< 3.2), those with moderate and highest DAS (3.2-5.1 & > 5.1) had worse outcome measures (p < 0.001). CONCLUSIONS: In this study, higher DAS was one of the most influential factors for poor PROs among all other factors. Therefore, we could suggest for appropriate treatment approaches according to DAS along with other significantly associated factors with PROs in the early stage of RA.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PMS67
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Musculoskeletal Disorders